Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Separation Science



View Channel

Microscopy | Image Analysis



View Channel

IT Solutions and Laboratory Automation



View Channel


Conferences | Events

Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics

publication date: Aug 25, 2020
author/source: Agilent Technologies


Additional high-volume manufacturing line in Colorado to produce high-quality molecules with potential for treating cancer, COVID-19, and other diseases

Agilent Technologies Inc. has announced it will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and RNA molecules used to create nucleic acid-based therapeutics. Oligos hold the potential to be used in developing treatments for cancer, COVID-19, cardiovascular disease, rare and infectious diseases, and other conditions. The expansion will more than double the current capacity for manufacturing therapeutic oligos at the Frederick site.

Agilent expects the supplier market for therapeutic oligos to exceed $750 million in 2025 with projected double-digit annual growth over the next five years. The addition of the higher-volume manufacturing line will help Agilent meet this growing demand from leading pharmaceutical and biotech companies. Customer shipments from the new line are expected to begin by the end of 2022.

“We are excited about the ongoing growth of the therapeutic oligo market and the continued strong interest in our oligo contract development and manufacturing organization services from existing and potential new customers,” said Sam Raha, president of Agilent’s Diagnostics and Genomics Group. “Adding this higher-volume line enables us to keep pace with demand while continuing to deliver a premium product with superior customer service. As a leading oligo manufacturer for more than 20 years, Agilent is uniquely qualified to support this critical and growing biopharma industry segment.”

Agilent is investing approximately $150 million to add 25,000 square feet of manufacturing capacity to the Frederick facility. The new capacity will also expand Agilent’s presence in Colorado, where the company has had an oligo manufacturing site in nearby Boulder since 2006. The Frederick facility, 30 miles north of Denver, has been operating since 2019. Both sites are current Good Manufacturing Practices (cGMP) facilities, as designated by the U.S. Food and Drug Administration.

“Today’s announcement reaffirms our commitment to Frederick and the state of Colorado,” Raha added. “The addition of another high-volume line will provide new jobs and new career opportunities that are unique to the area.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide.


more news from Agilent


If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners